Salarius Pharmaceuticals Inc (SLRX) Stock Analysis

Salarius Pharmaceuticals Inc (SLRX) is a publicly traded company in the HEALTHCARE sector. It trades at $0.84. This page summarizes the public market data, fundamentals, and frequently asked questions for SLRX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

About Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals Inc. (SLRX) is a clinical-stage biotechnology company headquartered in Houston, Texas, specializing in the development of innovative epigenetic therapies targeting cancer. With a strong commitment to addressing unmet medical needs, Salarius aims to advance its promising pipeline of treatments that leverage the unique mechanisms of epigenetics to improve outcomes for patients battling various malignancies. The company is dedicated to advancing its research through rigo...

GNG Research Analysis

GNG Research scores Salarius Pharmaceuticals Inc (SLRX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SLRX.

Frequently Asked Questions

Does SLRX pay dividends?

Salarius Pharmaceuticals Inc (SLRX) does not currently pay a regular dividend.